RA is the most frequent and most destructive inflammatory arthropathy. Rheumatoid factors, in spite of their lack of disease specificity, are important serological markers for RA and appear important in its immunopathogenesis as well. In search of more disease-specific autoimmune systems, we have screened a human placenta Xgtll cDNA expression library using selected sera from patients with classical erosive RA. We have identified one clone (RA-1) that is recognized by three of five screening sera. The 950-bp insert shows a complete nucleotide sequence homology to the cDNA encoding the two COOH-terminal domains of calpastatin. The deduced open reading frame of the RA-1 cDNA predicts a 284-amino acid protein, with a calculated mol wt of 35.9 kD. Calpastatin is the natural inhibitor of calpains, which are members of the cysteine proteinases recently implicated in joint destruction in rheumatic diseases. The two domains encoded by the RA-1 clone each contain the structural features associated with the inhibitory activity of human calpastatin. By Western blotting, 45.5% or 21/44 RA sera specifically recognized both the fusion and the cleaved recombinant protein. This is in contrast to 4.7% (2/43) in nonrheumatoid sera and 0/10 in normal sera. Anticalpastatin autoantibodies could represent a diseaseassociated marker in chronic erosive arthritis of the rheumatoid type and could hypothetically play a dual pathogenic role, directly via an immune interference and indirectly through an immune complex mechanism. (J. Clin. Invest. 1995Invest. . 95:1891
Introduction
Many manifestations of autoimmune diseases are characterized by their association with specific autoantibodies. In systemic lupus erythematosus, anti-dsDNA and anti-Sm autoantibodies can both serve as disease markers while only anti-dsDNA antibodies seem to have a pathogenic implication (1) . In Graves' disease and myasthenia gravis, antibodies respectively targeting the thyroid-stimulating hormone and the acetylcholine receptors may actually drive the disease process (2, 3) . Conversely, antithyroglobulin, antimicrosomal thyroid peroxidase, and antistriated muscle autoantibodies appear to act only as disease markers.
Several autoantibodies have been reported to be more closely associated with RA (4) (5) (6) (7) (8) . With the exception of rheumatoid factors, which are implicated in local immune complex formation and deposition, there is no evidence for a pathogenic role for these autoantibodies which may represent mere disease markers. A search for antigen-antibody systems more relevant to RA pathogenesis is thus warranted.
Isolation of cDNA clones encoding human proteins and peptides have been extensively used to identify new autoantigens (9) . We undertook the immunoscreening of a human placenta Xgt1 1 expression library with a pool of sera from five chronic erosive rheumatoid factor positive RA patients. In this study, we report that these sera recognized a cDNA clone (RA-1 ) l encoding a protein corresponding to the two most COOHterminal (residues 425-708) of the four inhibitory domains of calpastatin, the natural inhibitor of calpains (10) . Calpains are calcium-dependent cysteine proteinases which are important intracellular activators in the signaling pathways and in triggering apoptosis (11, 12) . They may also play a direct extracellular role in the destruction of connective tissue matrix and cartilage occurring in arthritic synovial joints ( 13) . We also demonstrate that a significant proportion (45.5%) of RA patients produce antibodies against the purified recombinant protein encoded by RA-1. These observations allow us to hypothesize that immune interference with the natural inhibition of these proteinases may have implications in the severe erosive features observed in a subgroup of RA patients.
Methods
Sera and antibodies. Sera were obtained from 44 patients who fulfilled the American College of Rheumatology criteria for RA (14) and were seen at the Rheumatic Diseases Unit of the Universit6 de Sherbrooke, Sherbrooke, Quebec, Canada. We used 53 control sera: 11 from systemic lupus erythematosus patients, 27 from osteoarthritic patients, 5 from patients with miscellaneous rheumatic diseases, and 10 from normal subjects. A pool of five RA sera positive for rheumatoid factor, antiperi-nuclear factor, and anti-Sa autoantibodies while negative for other RAassociated autoantibodies (against SS-A(Ro), SS-B(La), UlRNP, A2 hnRNP, histones, and vimentin), were selected for cDNA library screening. Anti-Sa antibodies were detected by Western blotting using a semipurified human placenta extract, as described (8) . These pooled sera were absorbed with Escherichia coli strain Y1090 lysates to deplete natural antibodies to bacteria, some of which are capable of crossreacting with autoantigens. A polyclonal goat antiserum specific for glutathione S-transferase (GST) (Pharmacia LKB Biotechnology, Inc., Uppsala, Sweden) was used to analyze the expressed fusion proteins.
Screening ofcDNA library with patient sera. A human placenta Xgtl 1 oligo(dT)-primed expression library of 2.4 x 106 clones (Clontech Laboratories Inc., Palo Alto, CA) was screened with the serum pool diluted 1/200 in Tris-buffered saline containing 0.05% Tween 20 (15) . This library was selected for its high number of recombinant clones and because placenta is a good source of Sa autoantigen, a specific disease marker for RA (8 Expression and purification of the fusion and recombinant proteins. The cDNA fragments were subcloned from pUCl9 into pGEX-4T-l (Pharmacia LKB Biotechnology Inc.). The pGEX-4T-l expression vector is constructed to give fusion polypeptides with an NH2-terminal GST carrier (27 kD) and a thrombin cleavage site (18). The E. coli PR745 lon-strain (New England Biolabs Inc.) was transformed with these constructs and the correct size and orientation of the cDNA insert was confirmed by restriction analysis with PstI digestion. Parental or recombinant pGEX-4T-1 transformants were grown at 37°C until OD595 reached 0.5-1.0 and induced with 1 mM isopropyl-/3-D-thiogalactopyranoside (IPTG) for 2 h. Cells were lysed and fusion proteins (referred to as GST-RA-1) were affinity-purified using glutathione Sepharose-4B (Pharmacia LKB Biotechnology Inc.), as described (18) . Recombinant proteins (rRA-l) were obtained by removing the GST carrier using 10 cleavage units of thrombin per milligram of fusion protein (Sigma Chemical Co., St. Louis, MO).
SDS-PAGE and immunoblotting. Bacterial lysates, fusion, and recombinant proteins were subjected to electrophoresis on reducing SDSpolyacrylamide gels (10%) and the protein bands were Coomassie blue stained or electroblotted onto nitrocellulose filters (8) . The blots were blocked with 5% dry milk in PBS, pH 7.3 and probed with an appropriate dilution of nonabsorbed serum in PBS-5% milk. Bound antibodies were detected with Protein A-horseradish peroxidase (ICN Biomedicals, Inc., Costa Mesa, CA) diluted in PBS-0.5% milk. Filters were developed using the enhanced chemiluminescence detection system (ECL; Amersham Corp.). Sera were coded and the immunoblots read blind. All sera were tested at least twice on each substrate; when the results were discordant for a given serum, the results of a third test was the one recorded. Sera giving indeterminate results (i.e., very faint bands) were read as negative.
Results
Isolation of the RA-1 cDNA clone. Approximately 2.5 X 106 plaques were immunoscreened and one strongly positive clone tide (position 1435-2384) and the predicted amino acid (position 425-708) levels (Accession number D16217, total nucleotides: 2,493 and total amino acids: 708). The RA-l cDNA ends at position 2384 of the published sequence of human calpastatin, 95 bp downstream from the stop codon, rather than at position 2,493, 204 bp downstream from the stop codon (19) . This has no effect on homology since the lacking base pairs are located in a noncoding region. The coding sequence of RA-1 cDNA contains a nucleotide substitution (G -+ A) at position 1937 of calpastatin cDNA; it would result in a glycine to glutamate replacement at position 592 of the calpastatin protein. The same nucleotide difference was found in a cDNA encoding domain 4 and all the 3' noncoding region, including the polyadenylation signal and the poly-A tail, that we recently cloned using a RA-1 cDNA-derived probe (data not shown). Interestingly, the deduced amino acid sequences of pig and rabbit calpastatins, aligned with human calpastatin sequence, also have a glutamate residue at position 592. This residue is situated in a highly conserved region (19) .
Expression of RA-J cDNA and purification of the fusion and recombinant proteins. The RA-1 cDNA was subcloned in the pGEX-4T-1 vector to express a recombinant protein in the accurate reading frame. GST-RA-1 expressed in E. coli PR745 lon-was affinity purified, eluted with glutathione (GST-RA-1), or the recombinant protein cleaved from its GST carrier (rRA-l). Both antigens were identified by SDS-PAGE and immunoblotting with the pool of RA sera (Fig. 2) . GST-RA-1 was of the expected M, of 65 kD (Fig. 2 A, lane 2) . Two major polypeptidic bands were affinity purified from IPTG-induced RA-1 bacterial lysates using a glutathione Sepharose column (Fig. 2 A, (Figure 2 A, lane 7), two of which were strongly recognized by the pool of RA sera ( Fig. 2 B, lane 7) and by its individual component sera (e.g., Fig. 3 B, lanes 1 and 2) . Although, the predicted mol wt of rRA-l is 36 kD, the two major antigenic bands migrated as proteins of 43 and 47 kD (Fig. 2 B, lane 7) . The 75-kD polypeptidic band (Fig. 2 B, lane 7) is an E. coli heat-shock protein produced by the dnaK gene that copurifies with the recombinant protein (20) and is recognized by natural antibodies in some nonabsorbed patient sera. The reactivity against this protein could be abolished after E. coli absorptions of the sera without depletion of anti-rRA-l antibodies (data not shown). A protein with an apparent Mr of 40 kD was recognized by some sera (Fig. 3 B) , independently of the recognition of the two rRA-l bands. For example, in Fig. 3 B, the serum in lane 1 only recognized the 43-and 47-kD rRA-l doublet, the serum in lane 10 recognized only the lower 40-kD band, while the sera in lanes 6-9 recognized all three bands. This suggests that the 40-kD band is not antigenically related to rRA-l. The absence of recognition of GST-RA-l by sera recognizing only the 40-kD band in the rRA-1 preparation further supports this interpretation (Fig. 3 A and B, Anti-Sa (-) 3 13 Non-RA patientst (n = 53) 2 51
* See Methods for breakdown of the non-RA group. All non-RA patients were anti-Sa negative.
Finally, the pool of sera failed to react with GST ( Fig. 2 B,  lanes 4 and 6) . Taken together, these results showed a strong reactivity of RA sera against the RA-1 polypeptides with a lack of detection of the GST moiety.
Reactivity of rheumatoid and control patients with fiusion and recombinant RA-J. To determine whether individual sera from RA patients reacted with the RA-1 polypeptides, Western blots were performed using purified GST-RA-1 and rRA-1 (Fig.  3 ). The results with both proteins were similar. The two rRA-1 polypeptidic bands (43 kD and 47 kD) were recognized by 21 of 44 RA sera (45.5%) vs two of 43 (4.7%) nonrheumatoid sera and none of 10 normal sera. The two nonrheumatoid sera had the clinical diagnosis of osteoarthritis. These data show that patients with rheumatic diseases produce autoantibodies recognizing a polypeptide (rRA-1) that corresponds to two functional domains of calpastatin. They also suggest that the production of anti-rRA-1 antibodies may be preferentially, but not exclusively, associated with RA. Because the library screening sera were anti-Sa positive and because the prevalence of anti-RA-1 and anti-Sa antibodies (8) in RA were similar, the 97 sera were also tested for anti-Sa antibodies by Western blot (Table I) . 31 RA sera were concordant (18 both positive and 13 both negative) and 13 were discordant (3 anti-RA-1 positive only and 10 anti-Sa positive only). The 53 control sera were all anti-Sa negative. Because these studies did not use full length calpastatin or pure Sa as antigens, it would be premature to conclude on the presence or absence of a molecular relationship between the two autoimmune systems.
Discussion
Autoantibodies to intracellular components expressed on cell surfaces or secreted in the extracellular environment are potentially pathogenic (1-3, 21 ). There is substantial evidence that many disease-associated autoantibodies have the ability to interact directly with enzymes and downregulate their activity (1, 21 ). Recent reports further suggest that autoantibodies can also upregulate enzymatic activity through interaction with proteinase inhibitors. Thus, anti-Cl-inhibitor antibodies have been detected in patients with severe episodes of angioneurotic edema and acquired Cl deficiency (22) . A subpopulation of antiproteinase 3 antibodies from patients with Wegener's granulomatosis can block the interaction of this serine proteinase with its natural inhibitor alpha 1-antitrypsin (23, 24) . The (25) . The RA-1 clone encodes two of the inhibitory sequences, those of domains 3 and 4 of calpastatin (Fig. 1) Proteolytic enzymes are thought to play an important role in joint destruction. These enzymes belong to three major families: the matrix metalloproteinases, the serine proteinases, and the cysteine proteinases (26) . The relative importance of these proteinases and their respective inhibitors in matrix destruction remains to be definitely established in vivo. However, recent data suggest that cysteine proteinases, particularly the calpains and their natural inhibitor calpastatin, could be important (27) (28) (29) . First, calpains are present in increased quantity in the synovial fluid (30-34) and membrane (13) . Second, they are secreted in vitro by TNFa and IL-i -stimulated synovial fibroblast-like cells (35) . Third, calpains are capable of degrading matrix components of articular cartilage and calpastatin can inhibit this degradation (29, 31, 32) . Fourth, a role for synthetic cysteine proteinase inhibitors as disease-modifying antirheumatic agents has been recently proposed in adjuvant-induced arthritis of rats and in collagen-induced arthritis of mice (36 One interesting observation is the discrepancy between the immunoreactivity of biochemically purified placental Sa antigen and of rRA-l. Indeed, absorption of sera with rRA-I did not completely deplete their anti-Sa reactivity (data not shown). A number of explanations are possible. First, rRA-I may lack epitopes found on the corresponding in vivo antigen: some epitopes may be situated on the NH2-terminal region of the protein that is not encoded by the RA-l clone, or rRA-I may lack antigenic posttranscriptional modifications. Second, some renaturation of the antigen blotted on nitrocellulose sheets is possible during immunoblotting; rRA-1 may thus lack some conformational epitopes found on the corresponding in vivo antigen. Third, anti-rRA-l and anti-Sa antibodies may represent linked, but not identical, autoantibody systems, similar to anti-Ro and anti-La or to anti-Ul RNP and anti-Sm (1) . The existence of anti-rRA-l antibodies within sera of some patients without antiSa antibodies supports this last hypothesis. Careful definition of the epitope(s) recognized by anti-Sa and anti-RA-l antibodies will be required to answer these questions.
The identification of calpastatin as an autoantigen in almost half of RA sera provide new research avenues. Studies are required to demonstrate the capacity of these antibodies to block the inhibitory activity of calpastatin on calpains. Furthermore, the presence of calpastatin-containing immune complexes should be demonstrated at the site of tissue damage in erosive RA. Finally, clinical correlation between the presence of anticalpastatin antibody and erosive disease will need to be systematically verified in RA and other rheumatic diseases, especially if an eventual therapeutic window is opened by synthetic cysteine proteinase inhibitors.
